Napredna pretraga

Pregled bibliografske jedinice broj: 322923

CSF levels of total tau, tau protein phosphorylated at threonine 181 and serine 199 as predictors of Alzheimer's disease in patients with mild cognitive impairment


Boban, Marina; Grbić, Kristina; Hof R. Patrick; Süßmair, Christine; Ackl, Nibal; Bader, Benedikt; Danek, Adrian; Šimić, Goran
CSF levels of total tau, tau protein phosphorylated at threonine 181 and serine 199 as predictors of Alzheimer's disease in patients with mild cognitive impairment // European Journal of Neurology
Brussels, Belgium: EFNS, 2007. str. 95-95 (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
CSF levels of total tau, tau protein phosphorylated at threonine 181 and serine 199 as predictors of Alzheimer's disease in patients with mild cognitive impairment

Autori
Boban, Marina ; Grbić, Kristina ; Hof R. Patrick ; Süßmair, Christine ; Ackl, Nibal ; Bader, Benedikt ; Danek, Adrian ; Šimić, Goran

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
European Journal of Neurology / - Brussels, Belgium : EFNS, 2007, 95-95

Skup
11th Congress of the European Federation of Neurological Societies

Mjesto i datum
Brisel, Belgija, 25-28.08.2007.

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Alzheimer's disease; cerebrospinal fluid; early diagnosis; ELISA; mild cognitive impairment; phoshorylated epitopes; tau proteins

Sažetak
Patients with mild cognitive impairment (MCI), especially those with the amnestic type of MCI, have an elevated risk for development of Alzheimer’ s disease (AD). Since treatment for AD is likely to have the best efficacy in the early or even preclinical phase of the disease, it is necessary to find biomarkers which would help to identify incipient AD in MCI cohorts. Our objective was to investigate the value of CSF total tau protein (t-tau), tau protein phosphorylated at threonine 181 (p-tau-181) and at serine 199 (p-tau-199) for the prediction of AD among patients with MCI. Patients with a clinical diagnosis of MCI-amnestic type as well as healthy controls were included. CSF levels of t-tau, p-tau-181 and p-tau-199 were measured using commercially available ELISA kits (Innogenetics, Ghent, Belgium ; Biosource International, Camarillo, CA, USA). After two years of follow-up MCI patients were divided in two groups: “ stable MCI” or “ MCI converters” (those who progressed to AD). Our preliminary results showed that CSF levels of t-tau and p-tau-181 proteins were significantly elevated in MCI converters compared to stable MCI patients and healthy controls. We therefore concluded that CSF levels of t-tau and p-tau-181 could be valuable markers of early AD in patients with MCI and, consequently, for early selection of patients for treatment.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti, Psihologija



POVEZANOST RADA


Projekt / tema
108-1081870-1942 - Fosforilacija tau proteina u razvitku i Alzheimerovoj bolesti (Goran Šimić, )

Ustanove
Medicinski fakultet, Zagreb

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE